For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

AOD-9604: origin, structure and research history

Research Library › GHRH & Ghrelin-Receptor

AOD-9604 is a synthetic 16-amino-acid peptide modeled on residues 177 to 191 at the C-terminal end of human growth hormone, with one added tyrosine. It was developed by a biochemistry group at Monash University in Australia in the late 1990s and taken into clinical development by Metabolic Pharmaceuticals. As of 22 Oct 2026 it is not approved as a medicine in any country, and an FDA advisory committee voted 12–0 in December 2024 against adding it to the 503A compounding bulks list.

Key facts

TypeSynthetic 16-amino-acid peptide (hexadecapeptide)
Derived fromHuman growth hormone, residues 177–191, plus an added tyrosine
First described2000, Monash University (Ng et al., Hormone Research)
Developed byMonash University; Metabolic Pharmaceuticals (founded 1998)
Designed targetLipid-metabolism signaling in adipose tissue (proposed, preclinical)
Regulatory status (Oct 2026)Not FDA-approved; not approved elsewhere; PCAC voted 12–0 against 503A listing (Dec 2024); named on WADA 2026 list (S2)

Who developed it

AOD-9604 came out of a biochemistry group at Monash University in Melbourne, Australia. The first full research paper on the compound, published in 2000, lists F.M. Ng as lead author alongside departmental colleagues [1].

In 1998 a company, Metabolic Pharmaceuticals, was formed around the Monash work. It held the program’s intellectual property and ran the compound’s human trials through the mid-2000s [2][3].

What it was designed to target

Human growth hormone is a 191-amino-acid protein with several distinct activities. Earlier research had associated a region near its C-terminal end with the hormone’s role in lipid metabolism. AOD-9604 reproduces residues 177 to 191 of that sequence and adds a tyrosine, giving a 16-residue peptide [3][4].

The design idea was to isolate that region as a stand-alone fragment that could be studied for lipid-metabolism signaling in adipose tissue, separately from the full hormone’s growth-promoting pathways. The proposed mechanism was characterized in rodent studies; FDA’s 2024 review describes the supporting data as largely preclinical [1][3].

Why it was created

AOD-9604 was originally investigated in a research program on obesity. Full-length growth hormone acts on many tissues and is known to affect blood glucose regulation, which made it a poor starting point for that program. The Monash team asked whether a small fragment could be separated from those broader actions [1].

Research timeline

  • Late 1990s: Developed and patented in Australia; Metabolic Pharmaceuticals founded in 1998 [2][3].
  • 2000: Monash publishes the first metabolic study of AOD-9604 in a rat model [1].
  • 2004: A phase 2 trial of about 300 participants reports results that draw analyst skepticism [5].
  • 2007: The larger OPTIONS trial, in 536 adults, does not meet its objectives; in February the company says it will not continue AOD-9604 as an obesity drug [3].
  • 2013: A human safety and tolerability analysis is published [4].
  • Nov 2024: FDA publishes its evaluation of AOD-9604 for the 503A bulks list [3].
  • Dec 2024: FDA’s Pharmacy Compounding Advisory Committee votes 12–0 against listing [6].

Regulatory status as of October 2026

As of 22 Oct 2026, AOD-9604 is not FDA-approved, and no approval in any other country has been identified. FDA evaluated it as a nominated bulk drug substance for 503A pharmacy compounding, and on 4 December 2024 the Pharmacy Compounding Advisory Committee (PCAC) voted 12–0 against adding it to the bulks list [3][6]. A separate compounding nomination was later withdrawn [3].

FDA’s page on safety risks of nominated bulk substances lists possible immunogenicity and reported serious adverse events for AOD-9604, while noting that causality is not clear [7]. On 14 October 2026 FDA sent an interim access policy on compounding certain peptides to the White House for review; its text and peptide list are not public [8].

AOD-9604 is named on the 2026 World Anti-Doping Agency Prohibited List under S2 (growth hormone fragments), prohibited at all times [9].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

Who developed AOD-9604?

AOD-9604 was developed by a biochemistry group at Monash University in Australia, with F.M. Ng as lead author of the first paper in 2000. Metabolic Pharmaceuticals, founded in 1998, ran its clinical development.

Is AOD-9604 FDA approved?

No. As of 22 Oct 2026 AOD-9604 is not FDA-approved, and an FDA advisory committee voted 12–0 in December 2024 against adding it to the 503A compounding bulks list.

What is AOD-9604 derived from?

It is a synthetic copy of amino acids 177 to 191 of human growth hormone with one added tyrosine, for 16 residues in total.

What happened to AOD-9604's clinical program?

After a 536-person trial did not meet its objectives, Metabolic Pharmaceuticals announced in February 2007 that it would not continue AOD-9604 as an obesity drug.

Is AOD-9604 on the WADA prohibited list?

Yes. It is named on the 2026 WADA Prohibited List under S2 growth hormone fragments, prohibited at all times.

Sources

  1. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000;53(6):274–278. Link
  2. Biotech Daily. CEO interview: Metabolic Pharmaceuticals, Roland Scollay (undated). Link
  3. US FDA, CDER. Evaluation of AOD-9604-related bulk drug substances for inclusion on the 503A Bulks List (briefing document). 5 Nov 2024. Link
  4. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7–15. Link
  5. BioWorld. Metabolic jumps, slides on trial data, analyst criticism. 22 Dec 2004. Link
  6. US FDA. Pharmacy Compounding Advisory Committee, 4 Dec 2024: final summary minutes. Approved 21 Feb 2025. Link
  7. US FDA. Safety risks associated with certain bulk drug substances nominated for use in compounding. Link
  8. Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026, pending review. Link
  9. World Anti-Doping Agency. 2026 Prohibited List (in force 1 Jan 2026): S2.2.3. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top